1,160 results on '"A. Muntañola"'
Search Results
2. P1277: MUTATIONAL LANDSCAPE AND COPY NUMBER ALTERATIONS IN TESTICULAR LARGE B-CELL LYMPHOMA
3. Testicular large B‐cell lymphoma is genetically similar to PCNSL and distinct from nodal DLBCL
4. New and Old Bauhaus: What Is Happening to Modern Architecture?
5. New therapies for relapsed or refractory aggressive B‐cell lymphoma increase survival: Analysis from the RELINF registry of the GELTAMO group
6. The Formalization of Architecture as a Social Dialogical Tool: An Introduction to Innovative Theoretical Frames in Architectural Design
7. Trends in hospitalisation for urinary tract infection in adults aged 18-65 by sex in Spain: 2000 to 2015.
8. EL ARTE EN ROSARIO DE ACUÑA
9. All-CLL: A Capture-based Next-generation Sequencing Panel for the Molecular Characterization of Chronic Lymphocytic Leukemia
10. Safety and tolerability of a 90‐minute rapid infusion of Sandoz biosimilar rituximab in B‐cell lymphoproliferative disorders in a real‐world setting
11. The Formalization of Architecture as a Social Dialogical Tool: An Introduction to Innovative Theoretical Frames in Architectural Design
12. Severity and organ distribution of graft‐versus‐host disease with post‐transplant cyclophosphamide versus calcineurin inhibitor plus methotrexate/mycophenolate mofetil or sirolimus in allogenic HLA‐matched or single‐allele mismatched stem cell transplantation
13. Testicular large B‐cell lymphoma is genetically similar to PCNSL and distinct from nodal DLBCL.
14. Rare Diseases in the Pediatric Population
15. Trends in hospitalisation for urinary tract infection in adults aged 18–65 by sex in Spain: 2000 to 2015
16. El futuro de la formación de los arquitectos y de las arquitectas tras cincuenta años de investigación
17. What is happening to modern architecture? = ¿Qué está sucediendo en la arquitectura moderna?
18. ¿Que esta pasando con la arquitectura moderna? (MOMA. New York, 1948)
19. Leyendo a Rosario de Acuña en su centenario. Visiones finiseculares para nuestro milenio
20. Results of R-ESHAP as salvage therapy in refractory/relapsed follicular lymphoma: a real-world experience on behalf of GELCAB group
21. RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group
22. New therapies for relapsed or refractory aggressive B‐cell lymphoma increase survival: Analysis from the RELINF registry of the GELTAMO group.
23. El Col·legi de Metges, Barcelona, 1964-1968 : Robert Terradas i Via, un outsider absolutament innovador
24. COMENTARIO DE LA SENTENCIA DEL TRIBUNAL SUPREMO DE 6 DE JUNIO DE 2019 (323/2019)
25. Party-appointed arbitrators in international commercial arbitration
26. A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome
27. All-CLL: A Capture-based Next-generation Sequencing Panel for the Molecular Characterization of Chronic Lymphocytic Leukemia
28. Early progression in follicular lymphoma in the absence of histological transformation or high‐risk Follicular Lymphoma International Prognostic Index still has a favourable outcome
29. Novel therapies for the treatment of relapsed‐refractory aggressive B‐cell lymphoma increase survival. Analysis from the RELINF registry of the GELTAMO group
30. FACTORS INFLUENCING SURVIVAL AND PROLONGED VIRAL REPLICATION IN PATIENTS WITH LYMPHOMA AND COVID‐19: AN OBSERVATIONAL COHORT STUDY FROM GELTAMO SPANISH GROUP
31. Leyendo a Rosario de Acuña en su centenario. Visiones finiseculares para nuestro milenio
32. El Col·legi de Metges, Barcelona, 1964-1968 : Robert Terradas i Via, un outsider absolutament innovador
33. Foreword
34. Early progression in follicular lymphoma in the absence of histological transformation or high-risk Follicular Lymphoma International Prognostic Index still has a favourable outcome
35. The interplay between architecture and education = El juego entre la arquitectura y la educación
36. Impact on Survival of the Introduction of New Therapies for Relapsed-Refractory Aggressive B-Cell Lymphoma, Based on the Relinf Registry: A Study By the Spanish Geltamo Group
37. Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real-World Setting in Spain: An Update of the Venares Study
38. Clinical Characterization, Prognosis and Therapeutic Management of 181 Patients with Splenic Marginal Zone Lymphoma (SMZL): Real World Experience of the Geltamo Group
39. Supplementary Table 1 from Differential Gene Expression Profile Associated to Apoptosis Induced by Dexamethasone in CLL Cells According to IGHV/ZAP-70 Status
40. Supplementary Table 2 from Differential Gene Expression Profile Associated to Apoptosis Induced by Dexamethasone in CLL Cells According to IGHV/ZAP-70 Status
41. Walkability as a Factor in the 15-minute City: A Comparative Analysis of Barcelona's Neighborhoods
42. Supplementary Table 2 from Differential Gene Expression Profile Associated to Apoptosis Induced by Dexamethasone in CLL Cells According to IGHV/ZAP-70 Status
43. Supplementary Table 1 from Differential Gene Expression Profile Associated to Apoptosis Induced by Dexamethasone in CLL Cells According to IGHV/ZAP-70 Status
44. Data from Differential Gene Expression Profile Associated to Apoptosis Induced by Dexamethasone in CLL Cells According to IGHV/ZAP-70 Status
45. Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial
46. El futuro de la formación de los arquitectos y de las arquitectas tras cincuenta años de investigación
47. First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial
48. ADVANCED-STAGE BREAST IMPLANT-ASSOCIATED LARGE CELL ANAPLASTIC LYMPHOMA. A RARE CASE OF MASS-LIKE BILATERAL DISEASE WITH AXILLARY INVOLVEMENT.
49. Impact on Survival of the Introduction of New Therapies for Relapsed-Refractory Aggressive B-Cell Lymphoma, Based on the Relinf Registry: A Study By the Spanish Geltamo Group
50. Clinical Characterization, Prognosis and Therapeutic Management of 181 Patients with Splenic Marginal Zone Lymphoma (SMZL): Real World Experience of the Geltamo Group
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.